ArticleClinical rheumatology2016
Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study.
Article in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- A systematic review of the association of obesity with the outcomes of inflammatory rheumatic diseases.Singapore medical journal · 2019Pooled it
- Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.Clinical rheumatology · 2017Trial
- Tocilizumab in German patients with RA: real-world evidence from the noninterventional studies ARATA and ICHIBAN.EULAR rheumatology open · 2026Review
- Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?Nutrients · 2025Article
- Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA.Rheumatology (Oxford, England) · 2025Article
- A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors.Turkish journal of medical sciences · 2023Article
- Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry.Turkish journal of medical sciences · 2023Article
- Review
- Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial.Arthritis research & therapy · 2021Article
- Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.International journal of molecular sciences · 2021Review
- Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland.Journal of clinical medicine · 2021 · on this mapArticle
- [The effect of obesity on disease activity of inflammatory rheumatic diseases].Zeitschrift fur Rheumatologie · 2021Review
- Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity.Frontiers in immunology · 2021Article
- Predicting treatment response to IL6R blockers in rheumatoid arthritis.Rheumatology (Oxford, England) · 2020Review
- Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.Rheumatology (Oxford, England) · 2020Article
- Obesity and its role in the management of rheumatoid and psoriatic arthritis.Clinical rheumatology · 2020Review
- The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition.Metabolites · 2020Review
- Body Mass Index and Clinical Response to Tocilizumab in Patients With Rheumatoid Arthritis.Archives of rheumatology · 2019Article
- Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have suggested that obesity could have a negative effect on response to anti-tumor necrosis factor α (anti-TNFα) in rheumatoid arthritis (RA). Little is known about the impact of body mass index (BMI) on other biologic agents. We aimed to evaluate the effect of BMI on response to tocilizumab (TCZ) in RA. RA patients treated with TCZ were included in this multicenter retrospective study. BMI was calculated at the initiation of treatment. After 6 months of treatment, change from baseline in DAS28, pain on a visual analog scale, erythrocyte sedimentation rate and C-reactive protein level, and tender and swollen joints were analyzed. The primary endpoint was decrease in DAS28 ≥ 1.2. Secondary outcomes were good response and remission by EULAR criteria. At baseline, among 115 RA patients included, the median (interquartile range) BMI was 25.4 (22.0-28.8) kg/m(2). The number of patients with normal weight, overweight, and obesity was 53 (46 %), 37 (32 %), and 25 (22 %), respectively. Baseline characteristics did not differ between the three subgroups of BMI. The median BMI did not differ between responders and non-responders for DAS28 decrease ≥1.2 (25.7 [22.1-29.9] vs 24.9 [22.0-27.1], P = 0.38), EULAR good response (25.9 [22.8-30.0] vs 25.4 [22.0-28.4], P = 0.61), and remission (25.1 [22.5-28.6] vs 25.4 [22.0-28.9], P = 0.76). BMI did not affect the response to TCZ in RA. If confirmed, these results could be helpful for the selection of a biologic agent in obese RA patients.
Indexed as
Identifiers
26801332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.